Literature DB >> 1955900

A double blind trial of botulinum toxin "A" in torticollis, with one year follow up.

A P Moore1, L D Blumhardt.   

Abstract

A double blind placebo controlled crossover trial was performed of botulinum toxin "A" in 20 patients with spasmodic torticollis. There was a statistically significant benefit for those treated with toxin; 12 on toxin improved objectively, compared with four on placebo (p less than 0.04). After a follow up period of one year, 16 still seemed to benefit from repeated toxin injections. The main side effect was dysphagia, which appeared to be dose related in individual patients.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1955900      PMCID： PMC1014522          DOI： 10.1136/jnnp.54.9.813

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  16 in total

1.  Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy.

Authors:  J Jankovic
Journal:  Adv Neurol       Date:  1988

2.  Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis.

Authors:  P Greene; U Kang; S Fahn; M Brin; C Moskowitz; E Flaster
Journal:  Neurology       Date:  1990-08       Impact factor: 9.910

3.  Visual electrical evoked potentials: evaluation of ocular injuries.

Authors:  L J Dorfman; M Gaynon; J Ceranski; A A Louis; J E Howard
Journal:  Neurology       Date:  1987-01       Impact factor: 9.910

4.  Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.

Authors:  M F Brin; S Fahn; C Moskowitz; A Friedman; H M Shale; P E Greene; A Blitzer; T List; D Lange; R E Lovelace
Journal:  Adv Neurol       Date:  1988

5.  Blink reflex studies in patients with focal dystonias.

Authors:  E Tolosa; L Montserrat; A Bayes
Journal:  Adv Neurol       Date:  1988

6.  The pathophysiology of cranial dystonia.

Authors:  A Berardelli; J C Rothwell; B L Day; C D Marsden
Journal:  Adv Neurol       Date:  1988

7.  Botulinum toxin in spasmodic torticollis.

Authors:  R Stell; P D Thompson; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

8.  Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.

Authors:  J Jankovic; K Schwartz; D T Donovan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-08       Impact factor: 10.154

9.  Pro-opiomelanocortin-derived peptides in transected and contralateral motor nerves of the rat.

Authors:  S Hughes; M E Smith
Journal:  J Chem Neuroanat       Date:  1989 Jul-Aug       Impact factor: 3.052

10.  Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis.

Authors:  D J Gelb; D H Lowenstein; M J Aminoff
Journal:  Neurology       Date:  1989-01       Impact factor: 9.910
View more
  12 in total

1.  What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.

Authors:  W Poewe; G Deuschl; A Nebe; E Feifel; J Wissel; R Benecke; K R Kessler; A O Ceballos-Baumann; A Ohly; W Oertel; G Künig
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

2.  Prospective study of swallowing function in patients with cervical dystonia undergoing selective peripheral denervation.

Authors:  A Münchau; C D Good; S McGowan; N P Quinn; J D Palmer; K P Bhatia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-07       Impact factor: 10.154

Review 3.  Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin.

Authors:  Maria Fiorella Contarino; Joost Van Den Dool; Yacov Balash; Kailash Bhatia; Nir Giladi; Johannes H Koelman; Annemette Lokkegaard; Maria J Marti; Miranda Postma; Maja Relja; Matej Skorvanek; Johannes D Speelman; Evelien Zoons; Joaquim J Ferreira; Marie Vidailhet; Alberto Albanese; Marina A J Tijssen
Journal:  Front Neurol       Date:  2017-02-24       Impact factor: 4.003

Review 4.  Botulinum toxin type A therapy for cervical dystonia.

Authors:  Mafalda Castelão; Raquel E Marques; Gonçalo S Duarte; Filipe B Rodrigues; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2017-12-12

Review 5.  Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology.

Authors:  A Berardelli; G Abbruzzese; L Bertolasi; G Cantarella; F Carella; A Currà; D De Grandis; G DeFazio; G Galardi; P Girlanda; P Livrea; N Modugno; A Priori; G Ruoppolo; L Vacca; M Manfredi
Journal:  Ital J Neurol Sci       Date:  1997-10

6.  Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.

Authors:  G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

Review 7.  Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.

Authors:  Wilhelm J Schulte-Mattler
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Experience with long-term treatment with albumin-supplemented botulinum toxin type A.

Authors:  Bahram Mohammadi; Katja Kollewe; Maresa Wegener; Hans Bigalke; Reinhard Dengler
Journal:  J Neural Transm (Vienna)       Date:  2009-03-25       Impact factor: 3.575

9.  Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance.

Authors:  J W Brans; I P de Boer; M Aramideh; B W Ongerboer de Visser; J D Speelman
Journal:  J Neurol       Date:  1995-08       Impact factor: 4.849

Review 10.  Immunogenicity of botulinum toxins.

Authors:  Markus Naumann; Lee Ming Boo; Alan H Ackerman; Conor J Gallagher
Journal:  J Neural Transm (Vienna)       Date:  2012-09-25       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.